Capricor Therapeutics, INC 8-K filings

Capricor Therapeutics announced the completion of enrollment for the Phase 3 HOPE-3 trial (Cohort A) for their Duchenne muscular dystrophy treatment, CAP-1002, and provided updates on their exosome platform.

Capricor Therapeutics shared a program update for its CAP-1002 Duchenne muscular dystrophy (DMD) program via a webcast on April 29, 2024.

Capricor Therapeutics reports completion of enrollment in a key Phase 3 trial for its Duchenne Muscular Dystrophy treatment, along with positive financial results and a strategic collaboration for a COVID-19 vaccine.

Capricor Therapeutics has received a $10 million milestone payment from Nippon Shinyaku after a positive review of its HOPE-3 trial.